Jeena Sikho Lifecare Limited filed a revised disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on May 9, 2026, in response to an email communication received from BSE Limited. The revision was made to incorporate the commencement and conclusion time of the Board Meeting held on May 8, 2026, during which the Board approved the sale of a non-operational land parcel in Punjab to Tresco Realty Group LLP for an aggregate consideration of ₹24,00,00,000/- (Rupees Twenty-Four Crores Only). The Board Meeting commenced at 5:00 PM and concluded at 5:30 PM. The Agreement to Sell was executed on May 7, 2026, and subsequently placed before the Board on May 8, 2026, for noting and formal approval. The intimation was signed by Manish Grover, Managing Director, on behalf of Jeena Sikho Lifecare Limited.

Key Transaction Details

The following table summarises the key parameters of the land sale transaction as disclosed under Regulation 30 of the SEBI Listing Regulations:

Nature and Purpose of the Transaction

The land being sold is non-operational in nature, with no business operations of the Company carried out on the said land. Accordingly, the Company has stated that the sale will not have any impact on its business operations. The transaction does not constitute a sale of an undertaking or substantially the whole of the undertaking in terms of Section 180(1)(a) of the Companies Act, 2013. The proposed transaction is also not part of any Scheme of Arrangement.

Related Party and Compliance Disclosures

The Company has confirmed that Tresco Realty Group LLP does not belong to the Promoter, Promoter Group, or Group Companies of Jeena Sikho Lifecare Limited. The transaction does not fall within the ambit of Related Party Transactions. None of the Promoters, Directors, Key Managerial Personnel, or their relatives are concerned or interested, financially or otherwise, in the transaction.

Completion and Payment Terms

The transaction is proposed to be completed upon fulfilment of conditions precedent, which include:

• Completion of partition (taksim) of the property
• Fulfilment of payment obligations
• Execution and registration of the Sale Deed as stipulated in the Agreement to Sell

The Agreement to Sell also provides for payment of earnest money, completion of due diligence, and payment of balance consideration in the manner agreed between the parties.

Regulatory Disclosure

The revised disclosure was made pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, as amended, and in accordance with SEBI circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026. The disclosure pertaining to turnover, revenue, or income contribution was noted as not applicable, as the transaction pertains to a non-operational land parcel and does not relate to the sale or disposal of any undertaking.

Jeena Sikho Lifecare Limited has informed the stock exchanges, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, about the publication of nine research works in the Journal of Applied Science and Education (JASE). The publications comprise seven case studies and two case reports, authored by medical professionals associated with the company, including its Managing Director, senior consultants, and Ayurvedic experts. The disclosure was made on 04 May, 2026.

Research Publications Overview

The nine publications collectively cover Ayurvedic clinical approaches to a range of medical conditions, reflecting the company's focus on evidence-based Ayurvedic practice. The authors include professionals directly associated with Jeena Sikho Lifecare Limited. The full details of all published works are presented below.

Scope of Clinical Research

The published works span several significant medical conditions addressed through Ayurvedic frameworks. The research areas covered across the nine publications include:

• Chronic Kidney Disease (CKD): Multiple publications addressing CKD at various stages, including End-Stage Renal Disease (Stage V), acute kidney disease, and CKD in combination with Type 2 Diabetes and Hypertension
• Musculoskeletal Conditions: Ayurvedic management of Gridhrasi (Sciatica) and Sandhigata Vata (Osteoarthritis)
• Paediatric Case: Ayurvedic treatment of kidney-related disorder (Vrikka Vikar) in a child
• Liver Condition: Management of liver cirrhosis (Yakritdalyodara) using Shamana Chikitsa and Panchakarma therapies
• Integrated Perspectives: Classical Ayurvedic disease pathology (Samprapti) and treatment (Chikitsa) for CKD with associated metabolic conditions

Regulatory Disclosure

The intimation was submitted to both the National Stock Exchange of India Limited and BSE Limited in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015. The disclosure was signed by Manish Grover, Managing Director (DIN: 07557886), from Zirakpur, Punjab, on 04 May, 2026. The company has also made the information available on its official website at www.jeenasikho.com . Links to all nine published articles have been provided to the exchanges for their records.